Actively Recruiting
Adaptive Anastomosis for Anterior Resection in Sigmoid and Proximal Rectal Cancer or Premalignant Lesions
Led by Amsterdam UMC, location VUmc · Updated on 2025-07-09
165
Participants Needed
1
Research Sites
127 weeks
Total Duration
On this page
Sponsors
A
Amsterdam UMC, location VUmc
Lead Sponsor
C
Carponovum AB
Collaborating Sponsor
AI-Summary
What this Trial Is About
Background: Anastomotic leakage (AL) after colorectal surgery remains a significant challenge, associated with increased morbidity, mortality, poor oncological outcomes, and reduced quality of life. Despite surgical advances, AL rates for colorectal procedures continue to range from 3% to 25%, especially in distal anastomoses. The commonly used cross-stapled circular anastomosis for anterior resections (AR) activates a foreign body response delaying gastrointestinal wound healing and potentially increasing the risk of AL. Additionally, crossed stapler lines further increase the risk of AL. An adaptive anastomosis technique eliminates permanent foreign body material, thereby reducing negative effects on wound healing and avoiding cross-stapling potentially lowering the incidence of AL. These areas have shown to have a lower burst pressure compared to a single stapled anastomosis. An adaptive anastomotic technique eliminates cross-stapling and permanent foreign body material in the anastomosis reducing the negative effects on wound healing potentially lowering the incidence of AL. Design: This is a prospective, international, non-randomized, multicentre study. Endpoints: The Primary objective of this trial is to assess the incidence of AL within 30 days after surgery. Secondary objectives are to assess anastomotic integrity at 90 days and 1 year, intraoperative efficacy and efficiency of the C-REX device, time to evacuation of the anastomotic ring, mode of evacuation and related patient experience, postoperative morbidity and readmissions, C-reactive protein (CRP) profile in the early postoperative period, functional outcomes, cost-effectiveness and surgical quality. Population: A total of 165 patients (age ≥ 18 years) with histologically proven cT1-4aN0-2M0 cancer of the sigmoid colon or proximal rectum, or premalignant lesions not amenable to endoscopic resection, that require elective AR will be enrolled throughout 10 European colorectal centers. Study procedures: The anastomosis will be created using the C-REX RectoAid Cath. The healing period will be approximately 10 days. The anastomotic ring detaches via necrosis and is evacuated with the feces. Patients will be asked to fill out questionnaires regarding Low Anterior Resection Syndrome (LARS) and use of healthcare and these will be gathered preoperatively, 90 days postoperative and 1 year after surgery. At 12 months a CT-scan and colonoscopy will be performed.
CONDITIONS
Official Title
Adaptive Anastomosis for Anterior Resection in Sigmoid and Proximal Rectal Cancer or Premalignant Lesions
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Biopsy proven cancer of the sigmoid colon or proximal rectum (cT1-4aN0-2M0) requiring anterior resection or premalignant lesions not treatable by endoscopic resection requiring anterior resection
- Suitable for curative anterior resection
- Suitable for elective laparoscopic or robotic surgery
- Ability to understand study information, provide informed consent, and complete questionnaires
You will not qualify if you...
- Emergency surgery needed due to intestinal obstruction, perforation, infection, peritonitis, or ischemia
- Cancer with distant metastases (Stage IV)
- Intestinal or anal stenosis or obstructions below planned anastomosis
- Prior pelvic radiation including neoadjuvant chemoradiotherapy
- Contraindications to general anaesthesia
- Need for defunctioning ileostomy
- Unable or contraindicated to receive preoperative bowel preparation or enemas
- Immunocompromised status such as steroid use or immunotherapy
- Conditions affecting colonic wall thickness like chronic infections that may impair device use
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Amsterdam UMC
Amsterdam, Netherlands
Actively Recruiting
Research Team
R
Roel Hompes, MD, PhD, FASCRS(hon)
CONTACT
L
Lodi Grosheide, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here